Bioxytran Inc
bioxytraninc.comWhat Do They Do?
Develops carbohydrate-based drug candidates for viral infections and injectable oxygen-carrying treatments for stroke and other oxygen-deprived tissues.
10-K for FY2025, filed Apr 15, 2026Bioxytran, Inc. is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and…View ↗
Our solution is an Acellular Oxygen Carrier (the “AOC”), which molecules hold the same amount of oxygen as the hemoglobin molecules in Red…View ↗
Our lead drug candidate, BXT-25, is a treatment modality intended to keep the brain tissue oxygenated and has no adverse effects. The…View ↗
We are a clinical stage pharmaceutical company focused on the development, manufacturing and commercialization of therapeutic drugs…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$619.9KView ↗
- ▼ Now a loss
- vs $35.4K in Q2 FY2025
Broader treatment focus
The older report focused on oxygen-deprivation conditions, while describing viral-disease drugs through Pharmalectin; the latest presents the company’s carbohydrate platform for viral infections and degenerative diseases alongside oxygen delivery.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 15, 2026
Loading...
